Tesamorelin
A genuinely FDA-approved peptide (for visceral fat in HIV lipodystrophy) that's widely used off-label for general body composition.
What is tesamorelin?
Tesamorelin is a stabilized GHRH analog and one of the few compounds in this library with full FDA approval. Sold as Egrifta, it was approved in 2010 to reduce excess visceral abdominal fat in people with HIV-associated lipodystrophy. That approval means it cleared real phase 3 trials, which puts its evidence base well ahead of the research-only secretagogues, even though the approved indication is narrow.
How tesamorelin works
Structurally it is human GHRH (1-44) with a chemical modification on one end that resists enzymatic breakdown, so it lasts longer than natural GHRH. It binds the GHRH receptor on the pituitary and stimulates the body's own pulsatile growth-hormone release, which raises circulating IGF-1. The downstream effect that earned its approval is a shift in fat metabolism that preferentially reduces visceral adipose tissue, the deep abdominal fat around the organs, rather than fat just under the skin.
What the research shows
This is the strong part. In a pooled analysis of two phase 3 trials totaling around 800 participants, tesamorelin reduced visceral adipose tissue by roughly 15% versus placebo at 26 weeks, along with improvements in triglycerides. That is exactly the kind of large, randomized, placebo-controlled human evidence most peptides here lack. The important boundary: this data is in HIV-associated lipodystrophy. Its use for general body composition in healthy people is off-label and far less studied.
Dosage and how it is used
The original FDA-approved dose is 2 mg by subcutaneous injection once daily. A later single-vial formulation (Egrifta SV) uses 1.4 mg daily with simpler preparation, and a newer weekly-reconstitution formulation has also been approved to reduce daily burden. All of this is for the approved HIV-lipodystrophy indication; off-label body-composition use does not have an established, validated protocol.
→ How to reconstitute tesamorelin: calculator, units to draw & storage
Side effects and safety
Because it raises GH and IGF-1, tesamorelin can cause the class-typical effects: joint pain, swelling and fluid retention, tingling in the hands, and injection-site reactions. Raising IGF-1 also means glucose metabolism needs watching, and it is not appropriate for people with active cancer or certain pituitary conditions. Its meaningful advantage over most of this list is that these risks were characterized in real FDA trials rather than left to guesswork.
- Research depth: extensive, FDA-approved with phase 3 data. Human clinical trials: yes.
- Approved evidence is specific to HIV lipodystrophy; general body-composition use is off-label.
- Raises IGF-1; not for active cancer. Verify current legal and regulatory status independently.
Frequently asked questions
Is tesamorelin FDA-approved?
Yes. It is approved as Egrifta to reduce excess visceral abdominal fat in people with HIV-associated lipodystrophy. That is a narrow indication, but it means the drug cleared real phase 3 human trials.
Does tesamorelin reduce belly fat?
In its approved population it does: pooled phase 3 trials showed roughly 15% reduction in visceral (deep abdominal) fat versus placebo at 26 weeks. Whether that translates to healthy people using it off-label is far less studied.
How is tesamorelin different from other GH secretagogues here?
It is FDA-approved with large randomized trial data behind it, which most peptides on this list do not have. The trade-off is that its proven benefit is specific to one medical condition rather than general anti-aging.
What are the side effects of tesamorelin?
The GH-class effects: joint pain, fluid retention and swelling, tingling in the hands, and injection-site reactions. Because it raises IGF-1, glucose needs monitoring, and it is not appropriate with active cancer.
References
Track Tesamorelin in Peptide AI
Log your doses, connect labs and wearables, and let the AI show you how Tesamorelin is affecting your biomarkers over time.
Download the appEducational information only. This is not medical advice. Peptide AI is an informational and tracking platform. Everything on this page is for general education. It is not a substitute for professional medical advice and is not a recommendation to use any compound. Many peptides listed here are research compounds the FDA has not approved for human use. Talk to a qualified, licensed healthcare provider before you start, change, or stop any protocol.